Point72 Asset Management’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
Point72 Asset Management's BBIO Position: Q3 2026 in Review
Point72 Asset Management reduced its BridgeBio Pharma (BBIO) stake by 61% in Q3 2026, selling an estimated $71.9M and leaving 602,374 shares worth $39.6M. The position accounts for 0.04% of the portfolio, ranked #556.
Point72 Asset Management first reported a position in BBIO in Q2 2019 and has held it in 8 quarters since. The position peaked at $114M in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- Point72 Asset Management held 602,374 shares of BridgeBio Pharma worth $39.6M as of Q3 2026.
- Point72 Asset Management sold 923,408 BridgeBio Pharma shares in Q3 2026, an estimated $71.9M.
- BridgeBio Pharma made up 0.04% of Point72 Asset Management's portfolio in Q3 2026, its #556 holding.
- Point72 Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 8 quarters since.
- Point72 Asset Management's BridgeBio Pharma position peaked at $114M in Q2 2026.
- 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.